Piper Sandler Maintains Overweight on Sutro Biopharma, Lowers Price Target to $12-Report Released on 14th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Sutro Biopharma (NASDAQ:STRO) but reduced the price target from $18 to $12, as reported on November 14, 2023.
November 15, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Sutro Biopharma but lowered the price target from $18 to $12.
The reduction in price target by Piper Sandler, despite maintaining an Overweight rating, suggests a more conservative valuation of Sutro Biopharma. This could lead to a negative short-term impact on the stock price as investors adjust their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100